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Abstract
Data on the effects of synbiotic supplementation on glycemic control, lipid profiles, and atherogenic index of plasma (AIP) of
women with polycystic ovary syndrome (PCOS) are limited. The purpose of this study was to assess the effects of synbiotic
supplementation on glycemic control and lipid profiles inwomenwith PCOS. A prospective, randomized, double-blind, placebo-
controlled trial was done at the Naghavi Hospital affiliated to Kashan University of Medical Sciences, Kashan, Iran, between
April 2017 and June 2017. Sixty women with PCOS were randomized to intake synbiotic capsule containing Lactobacillus
acidophilus strain T16 (IBRC-M10785), Lactobacillus casei strain T2 (IBRC-M10783), and Bifidobacterium bifidum strain T1
(IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were
taken at baseline and after the 12-week intervention to determine related variables. Compared with the placebo, synbiotic
supplementation resulted in a significant reduction in serum insulin concentrations (− 2.8 ± 4.1 vs. + 1.8 ± 6.4 μIU/mL, P =
0.002) and homeostasis model of assessment-insulin resistance (− 0.7 ± 1.0 vs. + 0.4 ± 1.5, P = 0.002), and a significant elevation
in the quantitative insulin sensitivity check index (+ 0.01 ± 0.01 vs. − 0.01 ± 0.03, P < 0.001). In addition, significant decreases in
serum triglycerides (− 16.2 ± 31.4 vs. + 5.8 ± 23.1 mg/dL, P = 0.003), VLDL-cholesterol concentrations (− 3.3 ± 6.3 vs. + 1.1 ±
4.6 mg/dL, P = 0.003), and AIP (− 0.05 ± 0.08 vs. − 0.003 ± 0.10 mg/dL, P = 0.03) were seen following the supplementation of
synbiotic compared with the placebo. Overall, we found that synbiotic supplementation to women with PCOS for 12 weeks had
beneficial effects onmarkers of insulin resistance, triglycerides, VLDL-cholesterol concentrations, and AIP, but did not influence
other lipid profiles. Trial registration: www.irct.ir: IRCT201604015623N71.
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Introduction
Polycystic ovary syndrome (PCOS) is a complex and het-
erogeneous endocrine disorder among women in the
reproductive age, which is commonly characterized by
hyperinsulinemia, dyslipidemia, hyperandrogenism, and
ovulatory dysfunction [1]. PCOS may cause increased risk
of metabolic disorders, including type 2 diabetes mellitus
(T2DM), gestational diabetes (GDM), cardiovascular dis-
eases (CVD), endometrial cancer, and other pregnancy-
related complications [2]. Many studies indicating gut mi-
crobiota could affect the nutrient composition and amino
acid utilization by the host [3–5]. The gut bacteria pertur-
bations may also altered metabolism of fatty acids in adi-
pose tissue and liver, gut peptide YY modulation, and se-
cretion of glucagon-like peptide-1 [3, 6]. Additionally, the
bacteria produce various amino acids that could be used as
precursors for the synthesis of fatty acids, which in turn
may lead to obesity [6]. Obese women can intense func-
tional hyperandrogenism and insulin resistance [7].
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It has reported that gut bacterial flora in obese patients are
significantly different from normal individuals [8]. Several
studies have also reported that probiotic bacteria have a po-
tential effect on treatment of metabolic disease [9, 10]. The
beneficial effects of probiotics, such as modulation of adipos-
ity and insulin resistance, have been deep-rooted in different
gut problems [11]. Other researchers have demonstrated that
the consumption of probiotics can cause catabolism of specific
amino acids [10, 12]. Earlier, we reported the beneficial effects
of probiotic in the treatment of metabolic profiles of women
with PCOS [13]. Moreover, another study has indicated that
probiotic intake could prevent the production of endotoxins
and compositions that lead to synthesis of adipose tissue [8].
Others also showed the lipid-lowering effects of probiotics.
For instance, Lactobacillus fermentum was significantly re-
duced LDL-cholesterol and triglyceride values in healthy in-
dividuals [14]. To our knowledge, there are insufficient data
regarding the role of synbiotic onmetabolic profiles of women
with PCOS. Only few limited studies have evaluated the in-
fluence of probiotic on weight loss, insulin resistance, and
lipid profiles in patients with PCOS [13, 15]. The aim of
current study was to assess the effects of synbiotic supplemen-




The present randomized, double-blind, placebo-controlled
clinical trial, registered in the Iranian registry of clinical trials
(http://www.irct.ir: IRCT201604015623N71), was carried out
among 60 patients with PCOS diagnosed according to the
Rotterdam criteria [16] and aged 18–40 years who were
referred to the Naghavi Hospital affiliated to Kashan
University of Medical Sciences (KAUMS), Kashan, Iran,
between April 2017 and June 2017. The research was
approved by the research ethics committee of KAUMS.
Smokers, intake of probiotics, and/or synbiotics supplements
within the last 3 months, pregnant women, other common
causes of hyperandrogenism, and/or anovulation, including
Cushing’s syndrome, androgen-secreting tumors,
hyperprolactinemia, and thyroid dysfunction, were excluded
in the study.
Study Design
Participants were randomized into two groups to receive either
one synbiotic capsule containing Lactobacillus acidophilus
strain T16 (IBRC-M10785), Lactobacillus casei strain T2
(IBRC-M10783), and Bifidobacterium bifidum strain T1
(IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin
(n = 30) and placebo (n = 30) per day for 12 weeks. Subjects
in the placebo group received the placebo that contained
starch but no bacteria. Shape and size of synbiotics and pla-
cebo capsules were similar and manufactured by Tak Gen Zist
Pharmaceutical Company, Tehran, Iran, and Barij Essence,
Kashan, Iran, respectively. Randomization assignment was
conducted using computer-generated random numbers.
Randomization and allocation concealment were conducted
by the researchers and participants and were carried out by a
trained midwife member at the gynecology clinic. All partic-
ipants were advised to maintain their routine dietary habits
without any changes in their other lifestyle factors such as
physical activity during the study. All women completed 3-
day food records and three physical activity records as meta-
bolic equivalents (METs) at weeks 0, 3, 6, 9, and 12 of the
treatment.
Treatment Adherence
To assess the compliance, subjects were asked to bring the
medication container. To increase the compliance, participants
received a short message on their cell phones to intake the
supplements daily.
Assessment of anthropometric measures
At baseline and after the 12-week intervention, all subjects
underwent standard anthropometric measurements: height
and weight (Seca, Hamburg, Germany). BMI was calculated
as weight in kg divided by height in meters squared [17].
Assessment of Outcomes
The primary outcomes were markers of glycemic control. The
secondary outcomes were markers of cardio-metabolic risk,
including lipid profiles and atherogenic index of plasma (AIP)
[18].
Biochemical Assessment
Ten-milliliter fasting blood samples were taken at weeks 0 and
12 of the intervention. To determine fasting plasma glucose
(FPG), serum triglycerides, VLDL-, total-, LDL-, and HDL-
cholesterol concentrations, we used enzymatic kits (Pars
Azmun, Tehran, Iran) [19]. All inter- and intra-assay coeffi-
cient variances (CVs) for FPG, lipid concentrations were low-
er than 5%. Circulating levels of serum insulin were quantified
using an ELISAKit (Monobind, CA, USA) with the intra- and
inter-assay CVs 3.0 and 4.6%, respectively [20]. The homeo-
static model of assessment for insulin resistance (HOMA-IR)
and the quantitative insulin sensitivity check index (QUICKI)
were determined according to suggested formulas [21]. AIP
was calculated based on suggested formulas [18].
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Statistical Methods and Sample Size
The Kolmogorov-Smirnov test was applied to control the nor-
mal distribution of variables. Independent-sample t test was
used to determine changes in anthropometric measures and
dietary intakes between the two groups. To determine the ef-
fects of synbiotic supplementation on glycemic control and
markers of cardio-metabolic risk, we used one-way repeat-
ed-measure ANOVA. To assess if the magnitude of the change
depended on the baseline values of biochemical parameters,
maternal age, and baseline BMI, we adjusted all analyses for
these variables to avoid the potential bias using analysis of
covariance (ANCOVA). P < 0.05 was considered statistically
significant. All statistical analyses were conducted using the
Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, IL, USA).
To calculate sample size, we applied the standard formula
suggested for clinical trials by considering type one error (α)
of 0.05 and type two error (β) of 0.20 (power = 80%). Based
on a prior study [22], we used 1.86 as SD and 1.5 as the
difference in mean (d) of HOMA-IR as key variable. Based
on this, we needed 25 participants in each group. Assuming 5
dropouts in each group, the final sample size was determined
to be 30 participants per group.
Results
As demonstrated in the study flow diagram (Fig. 1), during the
intervention phase of the study, two subjects were excluded
from the each group [withdrawn due to personal reasons (n =
2)]. However, as the analysis was done based on ITT princi-
ple, all 60 subjects with PCOS were included in the final
analysis.
Mean age, height, baseline weight, and BMI as well as their
means after the 12-week intervention of the participants were
not significant between synbiotic supplements and placebo
groups (Table 1).
Considering the 3-day dietary records obtained during the
intervention, there was no statistically significant difference in
terms of dietary macro- and micro-nutrient intakes between
synbiotic supplements and placebo groups (data not shown).
Compared with the placebo, synbiotic supplementation re-
sulted in a significant reduction in serum insulin concentra-
tions (− 2.8 ± 4.1 vs. + 1.8 ± 6.4 μIU/mL, P = 0.002), HOMA-
IR (− 0.7 ± 1.0 vs. + 0.4 ± 1.5, P = 0.002), and a significant
elevation in QUICKI (+ 0.01 ± 0.01 vs. − 0.01 ± 0.03,
P < 0.001) (Table 2). In addition, significant decreases in se-
rum triglycerides (− 16.2 ± 31.4 vs. + 5.8 ± 23.1 mg/dL, P =
0.003), VLDL-cholesterol concentrations (− 3.3 ± 6.3 vs. +
1.1 ± 4.6 mg/dL, P = 0.003), and AIP (− 0.05 ± 0.08 vs. −
0.003 ± 0.10 mg/dL, P = 0.03) were seen following the sup-
plementation of synbiotic compared with the placebo.
When we controlled the analyses for baseline levels of
biochemical variables, age and baseline BMI, FPG became
significant (P = 0.04), AIP became non-significant (P = 0.06)
and other findings did not change (Table 3).
Discussion
We found that synbiotic supplementation to women with
PCOS for 12 weeks had beneficial effects on markers of insu-
lin resistance, triglycerides, VLDL-cholesterol concentrations,
and AIP, but did not influence other lipid profiles. To our
knowledge, this study is the first report of synbiotic supple-
mentation on glycemic control, lipid concentrations, and AIP
among women with PCOS. It must be kept in mind that in the
current study, observed changes in markers of insulin metab-
olism in the synbiotic group compared with the placebo were
within the permitted standard ratios. Hyperinsulinemia and
insulin resistance in women with PCOS can result in the pro-
gression to T2DM and CVD later in life [2]. Therefore,
synbiotic supplementation due to its decreasing effects on
markers of insulin resistance may be useful to decrease com-
plications related to metabolic disorders. However, observed
changes at triglycerides and VLDL-cholesterol levels in our
study were statistically significant, but did not affect other
lipid profiles. Long-term interventions and higher dosage of
probiotic and inulin might result in greater changes in lipid
profiles.
PCOS is associated with carbohydrate intolerance, insulin
resistance, and increased lipid concentrations [23]. The cur-
rent study supported that synbiotic supplementation for
12 weeks to women with PCOS resulted in a significant re-
duction in serum insulin levels, HOMA-IR, and a significant
elevation in QUICKI compared with the placebo, but did not
affect FPG.We have previously indicated that taking probiotic
supplements had favorable effects on markers of insulin resis-
tance in patients with PCOS [13] and diabetic hemodialysis
patients [24]. In our previous study in women with PCOS, the
rate of decreased insulin, HOMA-IR, and triglycerides was
16, 18, and 12%, respectively, whereas in the current study,
the rate of decreased insulin, HOMA-IR, and triglycerides was
27, 30, and 12%, respectively. Furthermore, in that study,
probiotic supplementation could not affect AIP, whereas in
the current study, synbiotic intake significantly decreased
AIP. Shoaei et al. [15] also indicated that probiotics could
significantly reduce fasting glucose and insulin levels in wom-
en with polycystic ovary syndrome. Furthermore, Firouzi
et al. [25] observed that taking multi-strain probiotics for
12 weeks by patients with T2DM modestly improved
HbA1c and fasting insulin levels, but did not affect lipid con-
centrations. Improvements in markers of insulin metabolism
in the current study were in accordance with several studies
reported previously [26, 27]. In addition, a systematic review
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documented that some prebiotics and synbiotics have immu-
nomodulatory function and directly controlled hyperglycemia
and HOMA-IR [28]. Another study also reported probiotic
supplementation for 16 weeks to pregnant women could pre-
vent GDM [29]. Our previous study have showed a significant
decrease in insulin concentrations and HOMA-IR and a sig-
nificant increase in QUICKI without no change in FPG fol-
lowing the 12-week supplementation of probiotics in patients
with multiple sclerosis [30]. However, a 8-week supplemen-
tation with probiotics in women with PCOS has showed no
significant change in insulin resistance markers [15]. Obesity,
hyperinsulinemia and T2DM are important metabolic charac-
teristics of PCOS and common factors influencing liver func-
tion and generating nonalcoholic fatty liver disease [31]. In
addition, subjects with PCOS have an 11-fold increased risk
of metabolic syndrome compared with control subjects, even
in the same age range [32]. Probiotics and synbiotics may
increase glucagon-l ike pept ide 1 secret ion from
enteroendocrine L-cells to improve insulin metabolism and
decrease glucotoxicity [33]. In addition, synbiotics may im-
prove insulin metabolism through the modification of gut flo-
ra, the reduction of endotoxin levels, elevation of fecal pH
[34], and the reducing production of pro-inflammatory cyto-
kine [35].
This study exhibited that taking synbiotic supplements by
women with PCOS for 12 weeks was associated with a sig-
nificant reduction in serum triglycerides, VLDL-cholesterol
concentrations, and AIP compared with the placebo, but did
not influence other lipid profiles. In line with our findings,
Letexier et al. [36] reported that a 3-week supplementation
with 20 g inulin in healthy subjects had beneficial effect on
the treatment of hypertriglyceridemia. A meta-analysis study
Randomized (n=60) 
Allocated to placebo (n=30) 
Lost to follow-up (n=2) 
-Withdrawn (n=2) 
Analyzed (n=30) 
Allocated to intervention (n=30) 
Lost to follow-up (n=2) 
-Withdrawn (n=2) 
Analyzed (n=30) 
Assessed for eligibility (n=70) 
Excluded (n=10)  
- Not meeting inclusion criteria (n=5)  





















Fig. 1 Summary of patient flow
Table 1 General characteristics
of study participants Placebo group (n = 30) Synbiotic group (n = 30) P
a
Age (year) 27.3 ± 6.1 27.0 ± 5.6 0.87
Height (cm) 164.5 ± 6.8 163.8 ± 5.9 0.67
Weight at study baseline (kg) 74.4 ± 14.0 73.3 ± 11.5 0.75
Weight at end of trial (kg) 74.3 ± 14.2 73.2 ± 11.5 0.75
Weight change (kg) − 0.1 ± 0.9 − 0.1 ± 1.3 0.95
BMI at study baseline (kg/m2) 27.5 ± 5.3 27.3 ± 3.8 0.85
BMI at end of trial (kg/m2) 27.4 ± 4.3 27.2 ± 3.8 0.85
BMI change (kg/m2) − 0.1 ± 0.3 − 0.1 ± 0.5 0.94
Data are means ± SDs
aObtained from independent t test
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has showed that synbiotic supplementation to diabetic patients
significantly decreased triglycerides and total cholesterol
levels [37]. Mikelsaar et al. [14] also observed that a 8-week
administration of dairy Kefir containing L. fermentum ME-3
significantly reduced triglyceride concentrations in healthy
individuals. The consumption of L. fermentum ME-3 kefir
after a standard breakfast for 2 weeks in healthy subjects re-
sulted in a significantly reduced postprandial triglyceride re-
sponse [38]. In addition, an 8-week treatment of T2DM pa-
tients with synbiotic bread containing Lactobacillus
sporogenes and inulin for 8 weeks has showed a significant
reduction of triglycerides and VLDL-cholesterol levels [39].
However, Schaafsma et al. [40] demonstrated that synbiotic
supplementation for 3 weeks in male volunteers significantly
reduced total-, LDL-, and LDL-/HDL-cholesterol, whereas it
did not affect triglyceride levels. In the current study, the ab-
sent of beneficial effects of synbiotic supplementation on oth-
er lipid profiles might be explained by different study designs,
characteristics of study people, different dosages of probiotic
bacteria and inulin used, types and quality of probiotic bacte-
ria and inulin used, and duration of the intervention. Life-long
lipid metabolic dysfunction in subjects with PCOS
Table 2 Glycemic control and lipid profiles at baseline and after the 12-week intervention in subjects with polycystic ovary syndrome
Placebo group (n = 30) Synbiotic group (n = 30)
Baseline End of trial Change Baseline End of trial Change Pa
FPG (mg/dL) 94.0 ± 5.7 92.8 ± 8.1 − 1.2 ± 6.6 92.2 ± 6.2 88.0 ± 7.2 − 4.1 ± 9.1 0.16
Insulin (μIU/mL) 12.1 ± 6.3 13.9 ± 5.2 1.8 ± 6.4 12.9 ± 4.2 10.1 ± 3.9 − 2.8 ± 4.1 0.002
HOMA-IR 2.8 ± 1.4 3.2 ± 1.2 0.4 ± 1.5 3.0 ± 1.1 2.3 ± 0.9 − 0.7 ± 1.0 0.002
QUICKI 0.33 ± 0.03 0.32 ± 0.01 − 0.01 ± 0.03 0.32 ± 0.01 0.34 ± 0.02 0.01 ± 0.01 < 0.001
Triglycerides (mg/dL) 138.2 ± 37.9 144.0 ± 47.2 5.8 ± 23.1 146.4 ± 56.3 130.3 ± 39.3 − 16.2 ± 31.4 0.003
VLDL-cholesterol (mg/dL) 27.6 ± 7.6 28.8 ± 9.4 1.1 ± 4.6 29.3 ± 11.2 26.0 ± 7.9 − 3.3 ± 6.3 0.003
Total cholesterol (mg/dL) 168.3 ± 27.7 173.8 ± 28.5 5.5 ± 27.2 164.5 ± 23.7 163.2 ± 29.0 − 1.3 ± 27.3 0.33
LDL-cholesterol (mg/dL) 91.9 ± 27.9 93.8 ± 31.0 1.9 ± 31.7 90.8 ± 19.8 90.7 ± 31.1 − 0.1 ± 27.0 0.78
HDL-cholesterol (mg/dL) 48.8 ± 8.3 51.3 ± 16.1 2.5 ± 13.1 44.4 ± 8.8 46.4 ± 8.5 2.0 ± 4.2 0.84
AIP 0.44 ± 0.16 0.43 ± 0.22 − 0.003 ± 0.10 0.49 ± 0.20 0.43 ± 0.16 − 0.05 ± 0.08 0.03
All values are means ± SDs
AIP atherogenic index of plasma, FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment–insulin resistance, HDL-cholesterol high-
density lipoprotein-cholesterol, LDL-cholesterol low-density lipoprotein-cholesterol, QUICKI quantitative insulin sensitivity check index, VLDL-
cholesterol very low density lipoprotein-cholesterol
aP values represent the time × group interaction (computed by analysis of the one-way repeated-measure ANOVA)
Table 3 Adjusted changes in
metabolic variables in PCOS
patients
Placebo group (n = 30) Synbiotic group (n = 30) Pa
FPG (mg/dL) − 0.7 ± 1.3 − 4.6 ± 1.3 0.04
Insulin (μIU/mL) 1.6 ± 0.8 − 2.5 ± 0.8 0.001
HOMA-IR 0.3 ± 0.2 − 0.6 ± 0.2 < 0.001
QUICKI − 0.009 ± 0.004 0.009 ± 0.004 0.001
Triglycerides (mg/dL) 4.6 ± 4.6 − 15.0 ± 4.6 0.004
VLDL-cholesterol (mg/dL) 0.9 ± 0.9 − 3.0 ± 0.9 0.004
Total cholesterol (mg/dL) 6.2 ± 4.4 − 2.0 ± 4.4 0.19
LDL-cholesterol (mg/dL) 1.9 ± 5.0 − 0.2 ± 5.0 0.76
HDL-cholesterol (mg/dL) 2.5 ± 1.8 2.0 ± 1.8 0.85
AIP − 0.006 ± 0.01 − 0.05 ± 0.01 0.06
All values are means ± SEs
AIP atherogenic index of plasma, FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment–
insulin resistance, HDL-cholesterol high-density lipoprotein-cholesterol, LDL-cholesterol low-density lipopro-
tein-cholesterol, QUICKI quantitative insulin sensitivity check index, VLDL-cholesterol very low density lipo-
protein-cholesterol
a Obtained from repeated-measure ANOVA adjusted for baseline values of biochemical variables, age, and
baseline BMI
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exaggerates the risk for CVD with aging [41]. Furthermore,
surrogate outcomes, such as carotid intima changes are in-
creased in PCOS due to dyslipidemia [42]. Synbiotics may
improve triglycerides, VLDL-cholesterol values, and AIP by
lipolysis of triglycerides and transform triglyceride-rich parti-
cles into small [43], suppressing nuclear factor-kappaB [44],
and the effects on gut microbiota-short-chain fatty acid
(SCFA)-hormone axis [45].
Limitations
Our study due to the limited funding supports facing some
limitations; we could not assess the effect of synbiotics on
the SCFA of patient fecal, and also, our follow-up was in the
limited time. Longer follow-up probiotic administration may
affect other lipid profiles.
Conclusion
Overall, we found that synbiotic supplementation to women
with PCOS for 12 weeks had beneficial effects on serum in-
sulin, HOMA-IR, QUICKI, triglycerides, VLDL-cholesterol
concentrations, and AIP, but did not affect FPG, total-, LDL-,
and HDL-cholesterol levels.
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